Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

25805results about "Unknown materials" patented technology

Substituted tricyclic compounds as KRAS degraders

The present invention provides substituted tricyclic compound of formula (I), which are therapeutically useful as KRAS degraders. These compounds are useful in the treatment and / or prevention of diseases or disorders dependent upon KRAS. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof thereof.
Owner:AURIGENE ONCOLOGY LIMITED

Lactiplantibacillus plantarum strain having weight-reducing function, probiotic formulation, preparation method therefor, and use thereof

PCT designated stage expiredWO2025066317A1Antibacterial agentsBacteria
The present invention particularly relates to a Lactiplantibacillus plantarum strain having a weight-reducing function, a live bacterium formulation, a preparation method therefor, and the use thereof. The Lactiplantibacillus plantarum strain is preserved in China General Microbiological Culture Collection Center (CGMCC) of China Committee for Culture Collection of Microorganisms, the accession number thereof being CGMCC No. 25683. The Lactiplantibacillus plantarum strain and the live bacterium formulation thereof can inhibit the growth of an obesity bacterial strain Enterobacter cloacae, reduce the cholesterol, and inhibit the differentiation of 3T3-L1 preadipocytes, so as to reduce the body weight of an obesity model mouse and reduce the total weight gain and total food utilization rate of an obesity model rat, thereby achieving an excellent weight-reducing function.
Owner:COREE CO LTD

Spray dried inhalable biotherapeutics for the treatment of disease

The technology described herein is directed to spray-dried biotherapeutic matrix compositions comprising a bacterial preparation, which is formulated for administration by inhalation. Also described herein unit dosage forms of such spray-dried biotherapeutic matrix compositions, devices comprising such pharmaceutical compositions, methods of producing such pharmaceutical compositions, and methods of treating diseases, such as bronchopulmonary diseases, among others, using such spray-dried biotherapeutic matrix compositions.
Owner:ALVEOLUS BIO INC

Transmissible elements comprising pathway modification systems and exogenous nucleic acids for the production of molecules of interest

The present invention relates to transmissible elements (e.g. conjugative plasmids, phage and phagemid) which are engineered to express molecules of interest (MOIs) and a pathway modification system (PMS) which is able to introduce mutations in target endogenous genes in a recipient bacterium, or is able to produce nucleic acids which inhibit or increase expression of target endogenous genes in a recipient bacterium, or is able to express peptide inhibitor molecules which inhibit a target endogenous protein in a recipient bacterium. The invention relates to host cells containing the transmissible elements, to pharmaceutical compositions containing such transmissible elements or host cells, and their use in the treatment of various diseases.
Owner:SNIPR BIOME APS

Isolated ackermansiella muciniphila, composition comprising same and anti-aging and / or anti-oxidation use thereof

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.
Owner:MOON (GUANGZHOU) BIOTECH CO LTD

Bifidobacterium animalis subsp. Lactis for relieving ulcerative colitis and constipation and application thereof

The invention discloses bifidobacterium animalis subsp. Lactis for relieving ulcerative colitis and constipation and application of the bifidobacterium animalis subsp. Lactis, and belongs to the field of microorganisms. According to the invention, a strain of bifidobacterium anaticum subsp. Lactis LIHUO 01 is screened out, the strain is preserved in the Guangdong Microbial Culture Collection Center on November 20, 2024, and the preservation number is GDMCC No: 65512. The invention also discloses a preparation method of the bifidobacterium anaticum subsp. Lactis strain, and the bifidobacterium anaticum subsp. Lactis strain has the advantages that the bifidobacterium anaticum subsp. Lactis strain can be used for preparing the bifidobacterium anaticum subsp. Lactis strain; the bifidobacterium animalis subsp. Lactis LIHUO 01 has good in-vitro probiotic characteristics, has the effects of relieving ulcerative colitis, improving constipation and regulating intestinal flora, and has a good application prospect in preparation of food or health care products or medicines for relieving ulcerative colitis or improving constipation or regulating intestinal flora.
Owner:JIANGZHONG PHARMA CO LTD

Lactobacillus paracasei NCU-04 and application thereof

PendingCN119060902AStrong growth and reproduction abilityStrong acid resistanceAntibacterial agentsNervous disorderBiotechnologyHemolysis
The invention discloses a strain of Lactobacillus paracasei NCU-04 and application thereof, and relates to the technical field of microorganisms, the Lactobacillus paracasei NCU-04 is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms on August 8, 2022, and the preservation number is CGMCC No.25506. The Lactobacillus paracasei NCU-04 is named as Lactobacillus paracasei NCU-04, and the Lactobacillus paracasei NCU-04 is named as Lactobacillus paracasei NCU-04. The invention has the following beneficial effects: the strain has strong growth and reproduction capability, acid resistance and oxidation resistance, has no hemolysis capability and is sensitive to specific antibiotics; a bacterial liquid and a fermentation liquid of the strain have a relatively strong inhibition effect on salmonella typhimurium, shigella flexneri, beta hemolytic streptococcus, shigella dysenteriae and the like, and on a constipation mouse model, the strain can effectively relieve constipation symptoms through ways of regulating intestinal flora balance, relieving intestinal inflammation, regulating intestinal neurotransmitter and the like; and the depression-like behavior symptoms of constipation mice can be improved through a 5-HT signal pathway.
Owner:NANCHANG UNIV

Five-union bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome

The invention discloses a quintuple bacterium for conditioning and improving diarrhea, constipation and irritable bowel syndrome. The quintuple bacteria comprise lactobacillus reuteri HBM11-69, pediococcus pentosaceus MPL5, lactobacillus plantarum La-10, lactobacillus rhamnosus HBM11-35 and lactobacillus casei C7-2 bacteria, and the lactobacillus rhamnosus HBM11-35, the pediococcus pentosaceus MPL5, the lactobacillus plantarum La-10, the lactobacillus rhamnosus HBM11-35 and the lactobacillus The strain is found by a Lin Junjunch Teaching Team of South China Agricultural University. The probiotic composition disclosed by the invention is mutually matched and has a synergistic effect, and the intestinal flora structure balance can be effectively recovered by improving the small intestine propulsion rate, reducing the diarrhea frequency and the like. No matter in a viable or inactivated state, the traditional Chinese medicine composition has a relatively good improvement effect on gastrointestinal discomfort such as constipation and irritable bowel syndrome. The quintuplet compound probiotics are high in safety, do not cause adverse reactions such as electrolyte imbalance and can be used for preparing medicines or health foods or foods.
Owner:JIANMA PHARM (GUANGDONG) CO LTD

Preparation method of lactobacillus paracasei IOB413 bacterial powder for regulating and controlling butyric acid synthesis and application of lactobacillus paracasei IOB413 bacterial powder in immune direction

The invention relates to a preparation method of lactobacillus paracasei IOB413 bacterial powder for regulating and controlling butyric acid synthesis and application of the lactobacillus paracasei IOB413 bacterial powder in the immune direction. The preparation method comprises the following steps: carrying out strain activation on the lactobacillus paracasei IOB413; inoculating the activated strain into the optimized culture medium for culturing to obtain a secondary seed solution; inoculating the secondary seed liquid into a sterilized fermentation liquid culture medium for fermentation; and centrifuging the fermentation broth culture medium, collecting bacterial sludge, and freeze-drying the bacterial sludge to prepare the lactobacillus paracasei IOB413 bacterial powder. By optimizing the culture medium, the synthetic amount of butyric acid of the casei paracasei IOB413 in intestinal tracts can be remarkably increased, the influence of the casei paracasei IOB413 on intestinal functions by promoting butyric acid synthesis is further elaborated in detail, and finally the casei paracasei IOB413 has the effects of enhancing immunity, repairing damaged immune organs, improving intestinal injury, regulating intestinal microecology and the like.
Owner:TIANJIN INNOORIGIN BIOLOGICAL TECH CO LTD

Bifidobacterium animalis subsp. Lactis strain B21247 with hypoglycemic function and application thereof

The invention provides a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function and application thereof, and belongs to the technical field of functional microorganisms. The invention relates to a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function. The preservation number of the bifidobacterium animalis subsp. Lactis strain B21247 is GDMCC No: 65075. The strain B21247 has a good intestinal colonization function, and has the activity of inhibiting alpha-glucosidase in vitro. Meanwhile, a type 2 diabetes mouse model is used as an experimental model to verify that the strain B21247 achieves the effect of reducing blood sugar by adjusting glycosylated hemoglobin, reducing pancreatic beta cell damage and increasing secretion of intestinal GLP-1, and a new thought is provided for reducing blood sugar or treating diabetes.
Owner:AIAGE LIFE SCI CORP LTD

Bifidobacterium adolescentis YG3912, exosome and extract thereof and application of bifidobacterium adolescentis YG3912 in skin care

The invention relates to the field of microorganisms, in particular to bifidobacterium adolescentis YG3912, inactivated thalli, an extract, a culture, a culture supernatant, a fermentation product and / or a fermentation supernatant of the bifidobacterium adolescentis YG3912, an application of the bifidobacterium adolescentis YG3912 in preparation of a composition for promoting skin repair, reducing skin inflammation or allergy, improving skin quality and improving skin quality. The invention also relates to application of the composition in products for resisting skin aging and enhancing skin immune function. The bifidobacterium adolescentis YG3912 and the related products thereof have the advantages that the bifidobacterium adolescentis YG3912 and the related products of the bifidobacterium adolescentis YG3912 are high in skin cell repairing capacity, skin inflammation relieving, inhibiting or eliminating capacity and remarkable in skin aging resisting capacity, so that the bifidobacterium adolescentis YG3912 and the related products of the bifidobacterium adolescentis YG3912 are expected to be used for skin health care such as skin repairing, inflammation relieving and light aging resisting, and the bifidobacterium adolescentis YG3912 and the related products thereof have remarkable application value and market potential.
Owner:BEIJING YUJING PHARM CO LTD

Phytobacterium plantarum JN9, preparation, probiotic composition and application thereof

The invention relates to a plant lactobacillus JN9, a preparation, a probiotic composition and application thereof. According to the application, a new plant lactobacillus JN9 strain is obtained through screening, and the preservation number of the new plant lactobacillus JN9 strain is CCTCC (China Center for Type Culture Collection) NO: M 20241647. Through basic characteristic analysis (growth curve, acid resistance, cholate resistance and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolysis capability, toxin production capability, cytotoxicity and biogenic amine production capability), adhesiveness evaluation, GABA production evaluation and alcohol tolerance and acetaldehyde dehydrogenase production capability evaluation of the strain, the strain is found to be a safe strain; and the GABA has excellent GABA production performance, high alcohol tolerance and high acetaldehyde dehydrogenase activity. The composition can be applied to products for improving mood, such as relieving pressure, resisting depression, improving body sleep quality, reducing blood pressure, resisting diabetes, resisting cancer, resisting oxidation, resisting inflammation, resisting microorganisms, resisting allergy, enhancing alcohol tolerance in drinking, relieving discomfort after drinking and the like.
Owner:ADM (SHANGHAI) MANAGEMENT CO LTD

Lactobacillus kefiranofaciens IMAU12319 and application thereof

The invention discloses lactobacillus kefiranofaciens IMAU12319 and application thereof, belongs to the technical field of microorganisms, and particularly relates to lactobacillus kefiranofaciens IMAU12319 which is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 8, 2024, the preservation address is No. 3, No.1 yard, West Beichen Road, Chaoyang District, Beijing, and the number is CGMCC No.31224. The lactobacillus kefiranofaciens IMAU12319 has the advantages that the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319, and the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319; the invention also relates to an application of the lactobacillus kefiranofaciens IMAU12319 in preparation of a probiotic agent capable of resisting gastrointestinal digestion. The strain disclosed by the invention not only shows good gastrointestinal tract endurance capacity, but also shows relatively strong potential in the aspects of intestinal adhesion, oxidation resistance and bacteriostasis, and has a wide application prospect in leavening agent strains.
Owner:INNER MONGOLIA AGRICULTURAL UNIVERSITY

Composition for improving bone joint health and preparation method and application thereof

The invention provides a composition for improving bone joint health as well as a preparation method and application thereof, and relates to the technical field of bone joint health products. The composition for improving bone joint health is prepared from the following components in parts by mass: 0.5 to 5 parts of collagen peptide, 5 to 30 parts of mangosteen extract, 0.5 to 3 parts of non-denatured II type collagen peptide, 0.1 to 2 parts of milk mineral salt, 0.3 to 3 parts of bone collagen peptide, 0.1 to 2 parts of cartilage extract, 0.1 to 2 parts of N-acetylglucosamine, 0.1 to 2 parts of sodium hyaluronate and 0.3 to 3 parts of turmeric extract. The composition obtained by repeatedly compounding the mangosteen extract, the turmeric extract, the cartilage extract and the sodium hyaluronate has the advantages of low cost and high safety, and has a better effect on preventing or improving osteoarthrosis.
Owner:GUANGDONG JUNYUE NUTRITIONAL MEDICINE CO LTD

Composite metabiotic microbial inoculum for promoting vaginal micro-ecological balance and application of composite metabiotic microbial inoculum

The invention relates to a composite metabiotic inoculant for promoting vaginal micro-ecological balance and application thereof. Strain in the composite metabiotic inoculant for promoting vaginal micro-ecological balance comprises an inactivated LA88 strain and an inactivated N13 strain. The invention develops a brand-new probiotic intervention strategy for promoting the micro-ecological balance of the vagina, namely, the inactivated lactobacillus acidophilus LA88 strain and the inactivated lactobacillus plantarum N13 strain are compounded to form a brand-new composite metabiotic bacterial agent, and the composite metabiotic bacterial agent has a relatively good proliferation effect on various beneficial bacteria of the vagina, and can be used for preparing the probiotics for promoting the micro-ecological balance of the vagina. The traditional Chinese medicine composition has a strong inhibition effect on various vaginal pathogenic bacteria, and can promote recovery of a healthy microbial community structure.
Owner:CHONGQING BAIYA SANITARY PRODUCTS CO LTD

Reagent combination or kit for constructing intestinal organs and application of reagent combination or kit

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.
Owner:GUANGZHOU NAT LAB

Fat cutting filter, fat cutting filtering method and fat cutting filtering device

The invention relates to a fat cutting filter, a fat cutting filtering method and a fat cutting filtering device.The fat cutting filter comprises a shell, the interior of the shell is a treatment cavity, and the shell is provided with a first connector and a second connector which communicate with the treatment cavity; the cutting part is located in the treatment cavity and located between the first connector and the second connector, the cutting part comprises a rigid silk screen used for cutting fat, and the silk diameter of the rigid silk screen ranges from 0.05 mm to 1 mm. The mesh wires of the rigid silk screen are used for fat cutting, the structure is simple, operation is easy, convenient and efficient, the machining cost is low, the mesh diameter can be customized according to needs, the porosity can reach 90% or above, the cutting efficiency is high, and the problem of filtering blockage during fat cutting can be effectively solved.
Owner:SHANGHAI REJOIN MAOMO BIOTECHNOLOGY CO LTD

Phytobacterium plantarum MPs-68 capable of adsorbing micro-plastics and degrading uric acid and application of phytobacterium plantarum MPs-68

The invention relates to the technical field of microorganisms, in particular to plant lactobacillus MPs-68 capable of adsorbing microplastics and degrading uric acid and application of the plant lactobacillus MPs-68. The provided plant lactobacillus MPs-68 capable of adsorbing microplastics and degrading uric acid is a marine-derived natural strain, the preservation number is CGMCC No.31976, the plant lactobacillus MPs-68 has a remarkable adsorption effect on microplastics polystyrene and polyethylene, has the function of degrading uric acid, and is high in oxidation resistance, gastric acid resistance, cholate resistance and intestinal colonization capacity, and the plant lactobacillus MPs-68 can be used for adsorbing microplastics and degrading uric acid. The method has important application value in the fields of food or health care products for assisting adsorption of micro-plastics and reduction of uric acid and the like. The invention also provides a microbial agent, a probiotic product, a functional food, a fermentation product, a microecological preparation, a microplastic adsorbent and a microplastic adsorbent compounded with the lactobacillus brevis MPA01 (the preservation number is CGMCC No.31977) containing the phytobacterium plantarum MPs-68 capable of adsorbing the microplastics and degrading the uric acid, and the microplastic adsorbent has the effects of adsorbing the microplastics, degrading the uric acid and the like.
Owner:XIAMEN YUANZHIDAO BIOTECHNOLOGY CO LTD

Phytobacterium plantarum capable of promoting mineral absorption and transport and application thereof

The invention provides a plant lactobacillus capable of promoting mineral absorption and transport and application of the plant lactobacillus. The invention provides a plant lactobacillus of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.32404. The invention also provides a culture, a sterilized solution, a supernatant, a filtrate, a diluent, a precipitate or freeze-dried powder, a composition and a probiotic preparation containing the plant lactobacillus, and related applications and methods thereof.
Owner:INNER MONGOLIA MENGNIU DAIRY IND (GROUP) CO LTD

Bifidobacterium Longum Subsp. Infantis CCFM1269 and Application thereof

PendingUS20250082699A1BacteriaSkeletal disorder
The disclosure provides Bifidobacterium longum subsp. infantis CCFM1269 and an application thereof, and belongs to the technical field of microorganisms. The B. longum subsp. infantis CCFM1269 provided by the disclosure is a food safety strain, which has the effects of regulating the Th1 / Th2 balance and the IgA content of a mammal in an early life stage, enhancing the skeletal development, improving the femur length and skeletal steady state in the early life stage and the like, and thus the strain has a huge application prospect. Only a culture medium and control of some culture conditions are needed in a culture process of the strain, so that the cost is relatively low, and industrial production is easily implemented.
Owner:JIANGNAN UNIV

Limosilactobacillus fermentum VB216 and use thereof

PCT designated stage expiredWO2025021162A1BacteriaDigestive systemBiotechnologyDisease
Provided is a Limosilactobacillus fermentum VB216, which has the deposit number of CGMCC No. 26578 in the China General Microbiological Culture Collection Center, and has the deposit date of 20 February 2023. The Limosilactobacillus fermentum has inhibitory activities with regard to a variety of pathogenic bacteria and excellent activity for degrading arginine. The present invention can be used in the preparation of products, such as food, health-care food, medicine and feed, for preventing and / or relieving and / or treating arginine metabolism-related diseases, such as hyperarginemia, malignant tumor treatment, allergic reactions, eczema, pruritus and abdominal spasm, and has great application prospects.
Owner:HANGZHOU VICROBX BIOTECH CO LTD

Strain for improving bone health and application thereof

The invention provides a bacterial strain for improving bone health and application of the bacterial strain. The preservation number of bifidobacterium animalis subsp. Lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The strain can promote osteoblasts and inhibit osteoclasts in a cell experiment; by constructing a mouse model with abnormal bone growth, the BL-11 probiotics have an obvious improvement effect on bone development indexes of the model mouse, promote bone formation and inhibit bone resorption; furthermore, the BL-11 probiotics can improve the ostealgia score, life quality and bone mineral density of people with osteoporosis or bone mass reduction. The results indicate the application potential of the probiotics in improvement of abnormal bone growth and prevention and treatment of osteoporosis.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

Lactobacillus rhamnosus CBBM005 and application of lactobacillus rhamnosus CBBM005 in product for balancing intestinal flora, improving immunity and improving oral cavity

The invention relates to lactobacillus rhamnosus CBBM005 and application thereof in products for balancing intestinal flora, improving immunity and improving oral cavity, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CBBM005 is separated from human intestinal secretion, the lactobacillus rhamnosus CBBM005 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, and the preservation number is CGMCC NO.33904. The lactobacillus rhamnosus CBBM005 has the characteristics of balancing intestinal flora, improving immunity and improving oral cavity.
Owner:JIANGSU LANZE BIOTECHNOLOGY CO LTD

Exosome-containing eye drops as well as preparation method and application thereof

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.
Owner:MIWAIMI (ZHANGJIAGANG) BIOTECHNOLOGY CO LTD +1

Application of lactobacillus mucilaginosus TG018

The invention relates to the technical field of microorganisms, and in particular relates to application of a strain of lactobacillus mucus TG018. The invention further relates to a preparation method of the lactobacillus mucus TG018. The preservation number of the lactobacillus mucus TG018 is CCTCC (China Center for Type Culture Collection) No: M 2023514; the lactobacillus mucus TG018 can be used for producing nicotinic acid, serving as an antioxidant and / or preparing the antioxidant, or can be applied to medicines for reducing uric acid.
Owner:XIAMEN TREATGUT BIOTECHNOLOGY CO LTD

Application of bifidobacterium animalis in anti-inflammation, anti-helicobacter pylori and improvement of obesity, hyperlipidemia and bone loss

PendingCN119570671Aslow down weight gainreduce weightAntibacterial agentsBacteriaDiseaseBile salt hydrolase
The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.
Owner:DIPROBIO (SHANGHAI) CO LTD

Pediococcus acidilactici SWU-HX39 capable of relieving hyperuricemia

ActiveCN120060047ABacteriaAntipyretic
The pediococcus acidilactici SWU-HX39 with the uricemia reducing function is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33055, the preservation date is December 13, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici SWU-HX39 disclosed by the invention can be used for relieving kidney injury caused by hyperuricemia; synthesis of uric acid can be reduced, the concentration of uric acid in blood can be reduced, the excretion capacity of the body to the uric acid is improved, reabsorption of the body to the uric acid is reduced, and the effect of reducing the uric acid is achieved through two ways; in addition, the SWU-HX39 can be used for reducing the expression of LPS (Lipopolysaccharide), and reducing the expression of inflammatory factors IL-1beta, IL-6 and TNF (Tumor Necrosis Factor) alpha at the same time. The traditional Chinese medicine composition not only has the effects of resisting inflammation and relieving liver inflammation, but also can improve the SCFAs content, especially propionic acid, in the body of a hyperuricemia patient, so that the uric acid level is reduced, and the abnormal uric acid content is improved.
Owner:SOUTHWEST UNIV

Methods and compositions for diagnosis and treatment of metabolic disorders

Most disease-associated genetic loci map to more than one disease or trait, suggesting they act through multiple cell types and tissues giving rise to complex disease phenotypes. This pervasive pleiotropy of human diseases presents a tremendous burden on identifying mediating mechanisms and therapeutic targets. Multiple metabolic risk haplotypes are associated with risk for metabolic diseases. However, whether a haplotype actually causes a disease and the mechanisms that cause the disease are unknown. Integration of phenotypic and transcriptional profiling in primary human cells allows for functional characterization of disease-associated genetic variants. Applicants have analyzed multiple risk haplotypes and determined the function of risk haplotypes involved in causation of specific metabolic phenotypes, such as type 2 diabetes and lipodystrophy. Methods of treatments are disclosed herein.
Owner:THE BROAD INST INC +1